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Abstract
Background: Combination chemotherapy with oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) has
become a standard regimen for colorectal cancer. An increase of adverse events with combination
chemotherapy is predicted in elderly patients, and it remains controversial whether they should receive
the same chemotherapy as younger patients. Accordingly, this study of modified FOLFOX6 (mFOLFOX6)
therapy was performed to compare its safety between elderly and non-elderly patients.
Methods: We prospectively studies 14 non-elderly patients aged <70 years old and 8 elderly patients aged
≥ 70 years with unresectable advanced/recurrent colorectal cancer who received mFOLFOX6 therapy
during the period from March 2006 to March 2007. Adverse events and the response to treatment were
compared between the elderly and non-elderly groups.
Results: The main adverse events were neutropenia and peripheral neuropathy, which occurred in 62.5%
(≥ grade 3) and 87.5% (≥ grade 1) of elderly patients. The grade and frequency of adverse events were
similar in the elderly and non-elderly groups. In some patients with neutropenia, treatment could be
continued without reducing the dose of oxaliplatin by deleting bolus 5-fluorouracil. A correlation was
found between the cumulative dose of oxaliplatin and the severity of neuropathy, and there were 2 elderly
and 3 younger patients in whom discontinuation of treatment was necessary due to peripheral neuropathy.
The median number of treatment cycles was 10.0 and 9.5 in the non-elderly and elderly groups,
respectively. The response rate was 60.0% in the non-elderly and 50.0% in the elderly group, while the
disease control rate was 100% and 83.3% respectively, showing no age-related difference.
Conclusion:  mFOLFOX6 therapy was well-tolerated and effective in both non-elderly and elderly
patients. However, discontinuation of treatment was sometimes necessary due to peripheral neuropathy,
which is dose-limiting toxicity of this therapy.
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Background
A high response rate has been reported for FOLFOX ther-
apy that includes oxaliplatin in patients with unresectable
advanced/recurrent colorectal cancer, and this therapy is
now established as one of the standard treatment option
[1,2]. Since the introduction of oxaliplatin to Japan in
April 2005, FOLFOX therapy has also become widely used
in this country and is recommended as one of the stand-
ard treatments [3]. There are a number of versions of FOL-
FOX therapy among which modified FOLFOX6
(mFOLFOX6) allows more convenient administration
and has been adopted by many medical institutions in
association with popularization of outpatient chemother-
apy. However, there have been few adequate investiga-
tions into the safety and efficacy of mFOLFOX6 therapy. A
rapid increase in the incidence of colorectal cancer among
elderly Japanese persons is anticipated in the future, con-
sidering the current long average life span and the increase
in the incidence and mortality of colorectal cancer in
Japan. However, it remains controversial as to whether the
same multi-drug chemotherapy employed for younger
patients should also be given to elderly patients, because
an increase in the severity of adverse events is likely in the
elderly due to the decline of organ function associated
with ageing. Accordingly, the present study was per-
formed to examine the safety and efficacy of mFOLFOX6
therapy in patients over 70 years old.
Subjects and methods
Subjects
A multicenter study on the treatment of unresectable
advanced/recurrent colorectal cancer was started in 2006
by the Sanin Study Group on colorectal cancer (SSCC). To
determine whether mFOLOFX6 could be used safely to
treat unresectable advanced/recurrent colorectal cancer in
elderly patients, the present study (SSCC-0601) was also
performed by the SSCC.
Patients who met the following eligibility criteria and
received mFOFOX6 therapy at any of the three participat-
ing institutions (Division of Surgical Oncology, Faculty of
Medicine, Tottori University; Department of Digestive
and General Surgery, Faculty of Medicine, Shimane Uni-
versity; and Department of Surgery, Shimane Prefectural
Central Hospital) during the period from March 2006 to
March 2007 were enrolled.
The protocol was approved by the institutional ethics
committees and this study was carried out according to
the principles of the Declaration of Helsinki and Good
Clinical Practice guidelines.
The eligibility criteria were histologically proven unresect-
able colorectal adenocarcinoma; adequate bone marrow,
liver, and renal function; Eastern Cooperative Oncology
Group (ECOG) performance status (PS) <2; age >20 years
at the time of enrolment; and expected survival time >12
weeks. Any previous chemotherapy (only 1 regimen was
allowed) must have been completed at least 28 days
before enrolment. Postoperative adjuvant therapy was not
counted as prior chemotherapy. Patients with multiple
malignancies, comorbidities that could influence the out-
come, prior radiotherapy, pregnancy or lactation, sympto-
matic peripheral neuropathy, or a history of serious drug
hypersensitivity were excluded. Written informed consent
was obtained from all of the subjects.
Treatment schedule
An implantable port and a disposable pump were
employed so that chemotherapy could be administered
on an outpatient basis. An outline of the administration
method for mFOLFOX6 therapy, in which the dose of
oxaliplatin was reduced from 100 mg/m2 to 85 mg/m2, is
shown in Figure 1. A 5-HT3 antagonist and a steroid were
administered as premedication. A 2-hour intravenous
infusion of oxaliplatin plus l-leucovorin was followed by
bolus intravenous injection of 5-FU, after which 5-FU was
administered by continuous infusion for 46 hours. An
oral steroid was administered for 3 days from day 2 after
the start of therapy. The duration of one cycle was 2 weeks.
With each treatment cycle, administration was only
started after confirming that all of the following criteria
had been fulfilled.
(1) Hematological toxicity: leukocyte count >3,000/mm3
and platelet count >75,000/mm3.
(2) Non-hematological toxicity: Grade 2 or less according
to the National Cancer Institute Common Toxicity Crite-
ria (NCI-CTC), and Grade 1 or less for peripheral neurop-
athy.
(3) Even if these conditions for treatment were met,
administration could be postponed at the investigator's
discretion (e.g., for a rapid decrease of the leukocyte
count/platelet count, occurrence of jaundice, etc).
If any of the criteria were not met, treatment was post-
poned. The subsequent course could be postponed for up
to 21 days (excluding the scheduled day of starting
administration). If administration could not be com-
menced during this period, the study was discontinued.
Discontinuation of therapy
Administration was continued until any of the following
criteria for discontinuation were fulfilled.
(1) The patient was judged to have progressive disease
(PD), including clinical PD.Journal of Experimental & Clinical Cancer Research 2009, 28:109 http://www.jeccr.com/content/28/1/109
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(2) Adverse events occurred that made further administra-
tion difficult.
(3) The patient did not fulfill the administration criteria
and the next course of treatment could not be started by
21 days after the scheduled day of administration.
(4) A second dose reduction was considered to be neces-
sary (Table 1).
(5) Peripheral neuropathy of grade 3 or 4 occurred.
(6) The PS became 3 or higher.
(7) The patient refused further treatment.
(8) The investigator judged that continuation of the study
was difficult for any other reason.
Endpoints
The incidence and severity of adverse events were assessed
as the primary endpoints, while the duration of treatment,
antitumor effect (response rate, tumor stabilization rate,
and duration of response), and the safety and efficacy in
elderly patients were assessed as the secondary endpoints.
Adverse events and therapeutic efficacy were assessed
according to the NCI-CTC (version 3) (Cancer Therapy
Evaluation Program, NCI, Bethsada, Md., USA) and the
RECIST guidelines (version 3) [4]. Extramural review was
performed for judgment of the eligibility and handling of
registered patients, as well as for safety and efficacy assess-
ment.
Statistical analysis
The chi-square test for independence, Fisher's exact prob-
ability test, and the Mann-Whitney U test were used to
compare patient characteristics, treatment status, adverse
Schedule for mFOLFOX Therapy Figure 1
Schedule for mFOLFOX Therapy.
Table 1: Dose-Reduction Criteria and Dose to be selected at Dose-Reduction
Item Oxaliplatin 5-FU (bolus) 5-FU (infusion)
Neutrophil count < 500/mm3 85 → 85 400 → 0 2,400 → 2,400
Platelet count < 50,000/mm3 85 → 85 400 → 0 2,400 → 2,400
Non-hematological toxicity ≥ Grade 3 85 → 65 400 → 300 2,400 → 2,000
Skin symptoms ≥ Grade 3 85 → 85 400 → 300 2,400 → 2,000
Peripheral neuropathy Grade 2 85 → 65 400 → 400 2,400 → 2,400
Acute*1 laryngopharyngeal dysesthesia
(feeling of difficulty in breathing)
85 → 85
Infusion time is prolonged to
6 hours*2
400 → 400 2,400 → 2,400
Peripheral neuropathy ≥ Grade 3 Discontinuation
PS ≥ 3 Discontinuation
Abbreviation: PS, performance status
*1 During the period from administration of oxaliplatin to 2 hours after completion of administration.
*2 Administration of 5-FU should not be started until the completion of administration of oxaliplatin.Journal of Experimental & Clinical Cancer Research 2009, 28:109 http://www.jeccr.com/content/28/1/109
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events, and antitumor effect. A probability (P) value of
less than 0.05 was considered statistically significant for
comparisons between the younger and elderly groups.
The Kaplan-Meier method was used to estimate the time
to treatment failure (TTF).
Results
Patient profile
All of the 22 patients enrolled in this study were eligible.
Their median age was 66 years (range: 39–79 years),
including 14 non-elderly patients with a median age of
63.5 years (range: 39–69 years: younger group) and 8 eld-
erly patients with a median age of 74.5 years (range: 71–
79 years: elderly group). Although the elderly group had a
higher incidence of colon cancer (P = 0.011), there were
no marked differences of the other background factors
(Table 2).
Treatment status
The total number of cycles administered was 198, with a
median of 10.0 cycles per patient in the younger group
and 9.5 cycles in the elderly group, showing no difference
(P = 0.8912 by the Mann-Whitney U test). Postponement
of treatment due to toxicity occurred during 14.4% (18/
125) of the treatment cycles in the younger group and
6.8% (5/73) of the cycles in the elderly group (P = 0.1907
by the chi-square test for independence).
Adverse events
Adverse events that showed a high incidence included
neutropenia and peripheral neuropathy. The grade and
frequency of the other adverse events were similar
between the younger and elderly groups (Table 3). In 3
patients (one younger patient and 2 elderly patients) who
developed grade 4 neutropenia, treatment could be con-
tinued without reducing the dose of oxaliplatin by delet-
ing bolus 5-fluorouracil (Table 1). Peripheral neuropathy
of grade 1 or more occurred at an incidence of 86.4% in
the younger group and 87.5% in the elderly group (P =
0.7090), while grade 3 neuropathy occurred in 3 patients
(14.3%) from the younger group and 1 patient (12.5%)
from the elderly group (P = 0.7090) (Table 3). The inci-
dence of neuropathy in relation to the number of treat-
ment cycles is shown in Table 4. There was an increase in
the incidence along with the dose of oxaliplatin, and
grade 2 or worse neuropathy showed an incidence higher
than 50% during the 11th cycle in the younger group and
the 10th cycle in the elderly group (Figure 2).
Duration of Treatment
The time to treatment failure (TTF) was 6.2 months in the
younger group, and 4.9 months in the elderly group,
being slightly shorter in the latter group (Figure 3). The
major reasons for discontinuation of treatment were
tumor progression in 2 patients (14.3%) and peripheral
neuropathy in 3 patients (21.4%) from the younger group
versus 4 patients (50.0%) and 2 patients (25.0%), respec-
tively, in the elderly group (P = 0.0963 and 0.6199 by
Fisher's exact probability test). In the younger group, there
was also 1 case of discontinuation after re-resection and 2
patients discontinued treatment due to hematological
toxicity (a second dose reduction was necessary according
to the criteria in Table 1).
Response
Nineteen patients (12 from the younger group and 7 from
the elderly group) could be evaluated for their response to
treatment (Table 5). There were no patients with a com-
plete response. The response rate was 60.0% in the
younger group and 50.0% in the elderly group, while the
disease control rate (PR+SD) was 100% and 83.3% in the
younger and elderly groups, respectively. Thus, there was
no difference of the response in relation to age.
Discussion
In 1957, 5-fluorouracil (5-FU) became available clini-
cally, and the advent of 5-FU therapy [5,6] was followed
by 5-FU/leucovorin (LV) therapy [7] that has remained
standard chemotherapy for colon cancer for a very long
time. After irinotecan and oxaliplatin became available,
clinical studies including randomized comparative trials
[8-10] of concomitant treatment with these agents and 5-
Table 2: Patients Characteristics
< 70 Years (n = 14) ≥ 70 Years (n = 8) P values
Age (median) 63.5 [39–69] 74.5 [71–79] -
Sex (male/female) 11/3 5/3 *0.3695
PS (ECOG) 0/1/2 9/5/0 7/1/0 **0.2505
Primary tumor Colon/rectum/colorectal 4/8/2 7/1/0 *0.011/0.052/0.3939
Target lesions
liver/lung/LN/peritoneum/others
4/2/6/0/2 4/1/1/1/1 *0.291/0.709/0.161/
0.364/0.709
Previous surgery (+/-) 12/2 8/0 *0.3939
Adjuvant chemotherapy(+/-) 4/10 2/6 *0.6305
Previous treatment (+/-) 1/13 1/7 *0.6060
Abbreviation: PS, performance status; ECOG, Eastern Cooperative Oncology Group; LN, lymph node.
*P values for SEX, primary tumor, target lesions, previous surgery (+/-), adjuvant chemotherapy (+/-) and previous treatment (+/-) were calculated 
with the use of Fisher's exact probability test. **P values for PS were calculated with the use of Mann-Whitney U test.Journal of Experimental & Clinical Cancer Research 2009, 28:109 http://www.jeccr.com/content/28/1/109
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FU/LV were performed. As a result, combination therapy
with oxaliplatin + 5-FU/LV (FOLFOX4 or FOLFOX6) or
with irinotecan + 5-FU/LV (FOLFIRI) has become stand-
ard chemotherapy for unresectable advanced/recurrent
colorectal cancer in Western countries. Since the release of
oxaliplatin in Japan in April 2005, FOLFOX therapy has
rapidly become widespread, and it is described in the
Guidelines for Management of Colon Cancer [3] (pub-
lished in July 2005) as the standard therapy for unresect-
able advanced/recurrent colorectal cancer. FOLFOX4
therapy has thus become a standard therapeutic option
for advanced/recurrent colorectal cancer in many coun-
tries. In addition, FOLFOX6 [11] therapy without bolus
administration of 5-FU/LV on the second day has been
developed to reduce adverse reactions and simplify treat-
ment, and it is widely used as part of the trend for chem-
otherapy to be given on an ambulatory basis. Although
the safety and efficacy of L-OHP+5-FU/l-LV therapy (orig-
inal FOLFOX6) have already been investigated in Japan,
little has been reported about mFOLFOX6 therapy, in
which the dose of oxaliplatin is reduced to 85 mg/m2 (the
dose covered by the Japanese national health insurance
scheme) [12]. In addition, there is still no standard ther-
apy for elderly patients with colon cancer. Generally, the
pharmacokinetics of drugs in elderly patients differs from
those in younger patients due to decreased organ function
associated with aging [13,14]. As a result, adequate treat-
ment may not be provided to elderly patients compared
with non-elderly patients due to fear of adverse drug reac-
tions, and the examination of appropriate administration
methods for the elderly has not been pursued adequately.
In recent years, it has been confirmed that molecular-tar-
geting drugs, including bevacizumab, are effective for
colon cancer [15], and these drugs are already included as
part of standard therapy in Western countries. Kabbinavar
et al. reported that age had no influence on the safety of
Table 3: Major Adverse Events
Grade ≥ 3 < 70 Years (n = 14) ≥ 70 Years (n = 8) P values*
Leukocytopenia 2 [14.3%] 1 [12.5%] 0.7090
Neutropenia 4 [28.6%] 5 [62.5%] 0.1347
Anemia 0 [0.0%] 0 [0.0%] -
Thrombocytopenia 0 [0.0%] 0 [0.0%] -
Nausea 2 [14.3%] 0 [0.0%] 0.3939
Anorexia 1 [7.1%] 1 [12.5%] 0.6060
Fatigue 1 [7.1%] 1 [12.5%] 0.6060
Stomatitis 1 [7.1%] 0 [0.0%] 0.6363
Hand-foot syndrome 1 [7.1%] 0 [0.0%] 0.6363
Peripheral Neuropathy
Grade ≥ 1 12 [86.4%] 7 [87.5%] 0.7090
Grade ≥ 2 6 [45.5%] 4 [50.0%] 0.5464
Grade ≥ 3 2 [14.3%] 1 [12.5%] 0.7090
Grades of adverse events were defined according to NCI-CTC v3.0
*P values were calculated with the use of Fisher's exact probability test.
Table 4: Incidence of Peripheral Neuropathy during Treatment Cycles
< 70 Years (n = 14)
Cycles 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Grade1 346798 7 6 6 52221100
Grade2 011112 0 1 1 24321110
Grade3 000000 0 0 0 00100001
n 1 4 1 3 1 2 1 1 1 1 1 1 9 8 7 76642221
≥ 70 Years (n = 8)
Grade1 146544 6 4 4 22110000
Grade2 110011 0 1 0 21111000
Grade3 000000 0 0 0 00001000
n 888766 6 5 5 43222100
Grades of adverse events were defined according to NCI-CTC v3.0
*P values were calculated with the use of Fisher's exact probability test.Journal of Experimental & Clinical Cancer Research 2009, 28:109 http://www.jeccr.com/content/28/1/109
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the combined administration of bevacizumab with 5FU-
based chemotherapy [16], and concomitant use of a
molecular-targeting drug that may be less toxic is expected
to be a possible treatment option for elderly patients.
Since the release of bevacizumab in Japan in June 2007,
molecular targeting therapy has rapidly become wide-
spread, however, concomitant use of bevacizumab is still
often difficult in elderly patients because of concern about
serious adverse events such as thrombosis and gastrointes-
tinal perforation [15,17,18]. It is known that completing
the administration of 5-FU/LV, irinotecan, and oxaliplatin
according to the recommended schedule increases the sur-
vival time [19]. Thus, FOLFIRI and FOLFOX are still
needed for combined therapy and it is considered
extremely important to establish the safety of these regi-
mens in elderly patients.
Accordingly, we examined the safety and efficacy of
mFOLFOX6 therapy in elderly patients over 70 years old
when the dose of oxaliplatin was reduced to 85 mg/m2
(the dose covered by the national health insurance
scheme).
Colorectal cancer is currently the third highest cause of
cancer death and the second most common cancer in
Japan. Since the average lifespan is currently 78.6 years for
males and 85.6 years for females, a rapid increase of eld-
erly patients with colorectal cancer is predicted in this
country. Accordingly, it is problematic if elderly patients
cannot receive effective chemotherapy simply because of
their age, so the establishment of safe and effective stand-
ard therapy for elderly Japanese patients is important.
In Western countries, however, it is considered possible to
treat the elderly with standard therapy, provided that the
performance status (PS) is good, the function of major
organs is maintained, and there are no uncontrolled com-
plications. Goldberg et al. [20] reported that Grade 3/4
neutropenia and thrombocytopenia showed higher rates
in elderly patients, but there were no differences of the
response rate and safety of FOLFOX therapy between eld-
erly patients over 70 years old and younger patients as a
result of meta-analysis.
In present study, the elderly group was defined as patients
more than 70 years old to assess the safety and efficacy of
mFOLFOX6 therapy. We found that the incidence of
Grade 3–4 neutropenia tended to be higher in elderly
patients than younger patients, but there was no statistical
significance (62.5% vs. 28.6%, P = 0.1347). Also, the inci-
dence and severity of other adverse events in this study
were generally comparable to those reported in Western
countries [20]. The regimen was tolerable and there were
no deaths due to toxicity.
When setting the dose-reduction criteria and the method
of administration after occurrence of adverse events, it was
decided that the dose of oxaliplatin would not be reduced,
and that bolus 5-FU would be deleted due to the possibil-
ity that dose-limiting hematological toxicity such as neu-
tropenia (which showed a high incidence in this study)
might be caused by rapid intravenous injection of 5-FU
[21-23]. After bolus 5-FU was stopped in accordance with
the dose-reduction criteria (Table 1) due to grade 4 neu-
tropenia in 3 patients (one younger patient and 2 elderly
patients) during this study, treatment could be continued
safely until PD occurred. Peripheral neuropathy is a char-
acteristic adverse reaction to oxaliplatin and is the dose-
limiting toxicity of this drug. Occurrence of neuropathy is
dependent on the total dose of oxaliplatin, and grade 3–4
Occurrence of Peripheral Neuropathy in younger patients (left) and elderly patients (right) Figure 2
Occurrence of Peripheral Neuropathy in younger patients (left) and elderly patients (right). Abbreviation: G, 
Grade.Journal of Experimental & Clinical Cancer Research 2009, 28:109 http://www.jeccr.com/content/28/1/109
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neuropathy (NCI-CTC criteria) shows an incidence of
about 15% when the total dose reaches 750 to 800 mg/
m2[24]. The dose-dependent neuropathy caused by oxali-
platin is reversible after suspension/omission of the drug,
and treatment using a stop-and-go strategy (with reinstitu-
tion of therapy after recovery from toxicity) achieves favo-
rable survival [25] and is well tolerated by elderly patients
over 75 years old [26]. In the present study, neuropathy
showed a lower incidence than that mentioned above, but
there was a similar correlation between the total dose of
oxaliplatin and the severity of neuropathy in both the
younger and elderly groups (Figure 2).
Although the time to treatment failure (TTF) was 6.2
months in the younger group versus only 4.9 months in
the elderly group, the number of treatment cycles was
10.0 and 9.5, respectively, showing that administration of
mFOLFOX6 was possible in elderly patients with a good
PS. The response rate was 60.0% in the younger group and
50.0% in the elderly group, while the disease control rate
was 100% and 83.3%, respectively, showing no signifi-
cant difference in relation to age.
When this study was initiated in San-in, a rural region of
Japan with a large elderly population, there was an urgent
need to establish effective chemotherapy regimens for
colorectal cancer, which has recently become much more
common in Japan. Accordingly, the present study was
intended to assess the feasibility of mFOLFOX6 in Japa-
nese colorectal cancer patients, including elderly patients,
with regard to the incidence and severity of adverse events.
In an attempt to rapidly investigate the efficacy and safety
of mFOLFOX6, the subjects were enrolled during a 1-year
period. The limited duration of enrollment resulted in too
small a sample size for the study to be adequately pow-
ered. Despite this, our findings suggested that mFOLFOX6
is similarly tolerable and effective for elderly patients as it
is for non-elderly patients, because the therapy could be
administered at its recommended dosage without causing
more severe adverse events than in non-elderly patients by
employing appropriate criteria for patient selection, treat-
ment suspension, and dose reduction in consideration of
factors such as the PS and comorbidities.
However, discontinuation was necessary in 12 patients
(including 3 elderly patients) because of adverse reac-
tions, and 5 patients (including 2 elderly patients) discon-
tinued treatment due to peripheral neuropathy (the dose-
limiting toxicity of oxaliplatin). Therefore, avoiding or
reducing the occurrence of such adverse events is neces-
sary for the establishment of safer standard therapy.
Conclusion
It was confirmed by the present study that mFOLFOX6
therapy, a standard chemotherapy for unresectable
advanced/recurrent colorectal cancer, could be performed
safely in elderly Japanese patients. The tolerability and
efficacy of mFOLFOX6 therapy can be expected to be sim-
ilar in the elderly, provided that the PS is good, the major
organs are functioning well, and there are no uncon-
trolled complications.
The present findings also suggested that withdrawal of
bolus 5-FU to avoid severe neutropenia might allow the
continuation of treatment. Because discontinuation due
Time to Treatment Failure (TTF) Figure 3
Time to Treatment Failure (TTF). The Kaplan-Meier 
method was used to estimate TTF curves. Median value for 
each group is shown.
Table 5: Antitumor Effects
< 70 Years (n = 14) ≥ 70 Years (n = 8) P values*
RR (%) 60.0 50.0 0.5490
DCR (%) 100 83.3 0.3750
CR/PR/SD/PD/NE 0/6/4/0/2 0/3/2/1/1 -
Abbreviation: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable; RR, response rate 
(CR+PR); DCR, disease control rate (CR+PR+SD).
*P values were calculated with the use of Fisher's exact probability test.Journal of Experimental & Clinical Cancer Research 2009, 28:109 http://www.jeccr.com/content/28/1/109
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to peripheral neuropathy (the dose-limiting toxicity of
this regimen) was common, methods to avoid or alleviate
such adverse events without reducing efficacy need to be
investigated.
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